Renovos Biologics Appoints Lisa Ferrara, Ph.D. to Its Board

Renovos Biologics has appointed Lisa Ferrara, Ph.D. to its board as a non-executive director.
 
Dr. Ferrara has extensive experience developing new orthopedic devices in the U.S. and securing their regulatory approval. The appointment comes as Renovos moves forward with development of its lead product RENOVITE BMP-2, a next-gen precision drugs carrier.
 
Dr. Ferrara is a managing partner of technology consulting firm Hypoid Ventures. She previously founded OrthoKinetic Technologies and OrthoKinetic Testing Technologies, two companies that specialize in medical device evaluation, strategic positioning, and regulatory success. The companies were later acquired.
 
She also founded and directed the Spine Research Laboratory at the Cleveland Clinic Foundation, has authored more than 60 journal publications, and edited 26 book chapters. Dr. Ferrara has numerous patents to her name.
 
She is a member of several healthcare advisory boards and editorial boards. Dr. Ferrara is a member of the Orthopedic Design & Technology editorial board.

---

READ MORE: ODT’s Editorial Advisory Board Reflects on 15 Years

---

 “Renovos’ RENOVITE nanoclay technology represents a transformative platform in regenerative medicine, enabling localized delivery of therapeutic agents directly to tissue sites without unwanted migration,” Dr. Ferrara told the press. “It’s fantastic to be joining Renovos, whose technology holds the potential to usher in significant advancements in tissue regeneration, providing a promising solution not only for orthopedic treatments but for the future of regenerative medicine.”
 
“I’m delighted to welcome Lisa to Renovos,” added Renovos CEO Dr. Agnieszka Janeczek. “She brings a wealth of sector expertise in orthopedic devices and regulatory processes, largely from the USA. I am confident she will enhance our RENOVITE orthobiologic programs. Lisa’s expertise will be instrumental as we work towards first-in-human trials and further develop our pipeline of innovative therapies.”
 
Renovos was granted Breakthrough Device Designation by the U.S Food and Drug Administration (FDA) for RENOVITE BMP-2 in November 2023. RENOVITE BMP-2 offers retention of Bone Morphogenetic Protein 2 (BMP-2) at the target site of repair, leading to improved bone fusion, safety, and ease of use across spine procedures. This includes minimally invasive and endoscopic applications, as the formulation is injectable.